FIELD: immunology; medicine.
SUBSTANCE: use of a neutralizing antibody against RGMa is provided for the preparation of an agent for the prevention or treatment of peripheral neuropathy, as well as for the production of an agent for use in the prevention or treatment of pain symptoms associated with peripheral neuropathy or astrocytic damage. In addition, a method of preventing or treating peripheral neuropathy is provided, the said method comprises administering an effective amount of a neutralizing anti-RGMa antibody to a mammal in need thereof.
EFFECT: neutralizing antibodies against RGMa affect pain symptoms by improving not only peripheral neuropathies, but also astrocytic damage or hypofunctions.
20 cl, 4 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY MOLECULES AGAINST APRIL AND APPLICATIONS THEREOF | 2016 |
|
RU2793755C2 |
| ANTIBODY CAPABLE OF BINDING TO THYMIC STROMAL LYMPHOPOIETIN, AND USE THEREOF | 2020 |
|
RU2825304C2 |
| ANTIBODIES TARGETING C5aR | 2020 |
|
RU2823245C2 |
| ANTIBODIES TO ICOS | 2016 |
|
RU2742241C2 |
| ANTIBODIES TO ENTPD2, TYPES OF COMBINATION THERAPY AND METHODS FOR USING ANTIBODIES AND TYPES OF COMBINATION THERAPY | 2019 |
|
RU2790991C2 |
| ANTIBODY TO B7-H4, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2792748C2 |
| ANTIBODIES TO PD-1 AND THEIR APPLICATION | 2017 |
|
RU2761640C2 |
| ANTIBODY TO PD-L1, ITS ANTIGEN-BINDING FRAGMENT, AND THEIR PHARMACEUTICAL USE | 2019 |
|
RU2778085C2 |
| ANTIBODY TO IL-13RA2 AND ITS APPLICATION | 2018 |
|
RU2756623C2 |
| 5-BROMO-2,6-DI - (1H-PYRAZOL-1-YL)PYRIMIDINE-4-AMINE FOR USE IN CANCER TREATMENT | 2016 |
|
RU2745560C2 |
